David Scott, M.S., Ph.D.
David W. Scott, M.S., Ph.D.
Name: David W. Scott, M.S., Ph.D.
Regulation of adverse immune responses
Hemophilia, Multiple sclerosis
University of Chicago, Chicago, IL MS 1964 Microbiology
Yale University, New Haven, CT Ph.D. 1969 Immunology
*Left after 3 years w/o degree to begin grad work
Oxford University, England '70-'72
Dr. Scott has contributed to over 200 research papers on several subjects in immunology, focusing on immunologic tolerance, gene therapy, and most recently on engineering regulatory T cells for application in autoimmune diseases and hemophilia. He is the author of two textbooks, including a monograph entitled, The Nature of Immunologic Tolerance, and recipient of a number of awards, including the Distinguished Service Award from the American Association of Immunologists (AAI, 2004), a Boerhaave Professorship at Leiden University Medical School, The Netherlands (2006) and the 2009 Scientific Achievement Award from the American Association of Pharmaceutical Scientists.
Active in science education, Dr. Scott has been Chair of Education Committees at the American Society for Microbiology and AAI. He has also served on the editorial boards of major immunologic journals, and as a member of National Multiple Sclerosis Society, Juvenile Diabetes Research Foundation and NIH Study Sections.
Representative publications, projects, and/or deployments
- Jane Coffin Childs Postdoctoral Trainee, Oxford, England (1969-70)
- Research Career Development Awardee, NIH (1975-80)
- Eleanor Roosevelt Fellow, International Union Against Cancer (1976-77; 1986)
- Dean's Professor of Immunology, University of Rochester Medical Ctr. (1983-1994)
- Distinguished Service Award, American Association of Immunologists (2004)
- Boerhaave Professor, Leiden University Medical School, The Netherlands (April-May 2006)
- Scientific Achievement Award, American Assoc. Pharmaceutical Scientists (2009)
- I was drawn to immunology because of ‘specificity’ and endeavored to understand the nature of tolerogenic signals from the single cell to the whole organism level. My efforts to develop novel approaches to achieve immune tolerance include the use of isolated specific B cells, analysis of IgM versus IgD signals in B cell lymphoma models of apoptosis, use of Fc fusion proteins and B-cell presentation of those proteins, the discovery of regulatory epitopes, gene therapy for tolerance and engineered Tregs
- Engineered regulatory T cells for hemophilia and autoimmunity
- Nanoparticles for tolerance
- Fc fusion proteins